Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris.
Ocular iris metastasis from lung cancer is uncommon. We report a patient with metastatic non-small cell lung cancer who was found to have a metastatic lesion to the iris. Local therapy for pain control and vision loss was administered with intracameral bevacizumab. Complete resolution of pain, improvement in vision, and near complete resolution of iris tumor were seen within two months. No ocular toxicity to anterior segment structures was detectable on corneal pachymetry and corneal specular microscopy. This is the first case report demonstrating safety and efficacy of intracameral bevacizumab for iris metastasis from non-small cell lung cancer.
The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin;
Jonathan C
JC
Schell
The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin;
Steven B
SB
Koenig
Radiation Oncology Associates Ltd., St Luke's Medical Center, Milwaukee, Wisconsin, USA.
Kenneth
K
Bastin
The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin;
William J
WJ
Wirostko
bevacizumab; iris metastasis.; non-small cell lung cancer